With earlier detection and improved survival from early stage prostate cancer, it is likely that the numbers of men presenting with hypogonadal symptoms following curative surgery for their cancer will increase. Although testosterone supplementation is effective in improving symptoms of hypogonadism, traditionally such therapy has been contraindicated in patients who have had prostate cancer. This paper reviews the evidence that testosterone therapy can be safely given to selected men with hypogonadism who have had prostate cancer but currently have no evidence of disease by clinical and prostate-specific antigen (PSA) criteria. Such patients should be treated cautiously and followed closely.
Introduction
With increasingly earlier diagnosis of prostate cancer, it is likely that clinicians will see an increase in the number of patients who have had treatment for curative purposes. Since both prostate cancer and late onset hypogonadism (LOH) occur frequently after the age of 50 years, some cancer patients may also present with symptoms of LOH and low serum testosterone levels. Severe and sustained hypogonadism may also result from transient androgen suppression therapy with luteinizing hormone-releasing hormone (LH-RH) agonists for patients with prostate cancer. 1 Testosterone supplementation is effective in improving sexual dysfunction and other symptoms of hypogonadism in men with primary or secondary hypogonadism. [2] [3] [4] [5] However, traditional thinking discourages the use of testosterone replacement therapy in men with a history of prostate cancer; in 2002, the Third International Consensus Consultation on Prostate Cancer recommended that patients with prostate cancer never receive testosterone supplementation therapy. 6 It is not routine in urologic practice to evaluate serum testosterone levels or to attempt to lower them in those who receive attempted curative surgery or radiation for prostate cancer, suggesting that being eugonadal is not detrimental to these prostate cancer patients. The major concern in treating LOH is the possible development or unmasking of prostate cancer, although there is no evidence that testosterone therapy is causative. Recent evidence, however, suggests that selected men with hypogonadism following radical prostatectomy for prostate cancer can safely receive testosterone replacement. 7 
Prostate cancer and testosterone
It is known that males castrated before puberty and those with androgen insensitivity syndromes do not develop prostate cancer. However, most studies do not show a consistent relationship between serum testosterone levels and the disease. A review of 25 studies comparing testosterone levels in a total of 2767 controls and 1481 patients with prostate cancer found the mean testosterone levels at diagnosis to be the same in both groups in 15 studies (60%), higher in prostate cancer patients in four (16%) and lower in six (24%). 8 A meta-analysis of all previously published studies on hormonal predictors of risk for prostate cancer performed in 2000 found only three cohort and case -control studies that met their criteria -mutual adjustment for all measured serum hormones, age and body mass index. 9 From the data from these three studies, the authors concluded that men whose total testosterone was in the highest quartile were 2.34 times more likely to develop prostate cancer than patients with testosterone levels in the lowest quartile. This conclusion, however, must be seen in light of the fact that one study had a disproportionally high impact on the results of this meta-analysis. A quantitative review of the data from eight prospective epidemiological studies, comparing mean serum concentrations of sex hormones in men who subsequently developed prostate cancer (n ¼ 644) with those in men who remained cancer free (n ¼ 1048), found no differences in circulating androgens between men who later developed prostate cancer and those who did not, with the possible exception of androstanediol glucuronide, which exhibited a 5% higher mean serum concentration among cases relative to controls. 10 In a recent prospective study of 759 men in the Baltimore Longitudinal Study on Aging, 111 developed prostate cancer. An increased risk of prostate cancer was found to be associated with higher serum-free testosterone but not total testosterone. In addition, higher serum hormone-binding globulin decreased risk and being eugonadal resulted in higher risk than being hypogonadal. 11 An inverse relationship between hormone-binding globulin and prostate cancer risk was also shown in the one study from the previously described meta-analysis that provided multivariably adjusted data (Table 1) . 9 Some studies suggest that lower serum testosterone levels in men with prostate cancer may be associated with more aggressive disease. In a review of 879 patients treated by radical prostatectomy, patients with non-organ-confined prostate cancer showed lower pretreatment testosterone levels than those with organ-confined disease (348.9 versus 373.2 ng/dl, respectively), and in multivariate analysis, pretreatment total testosterone was a significant independent predictor of extraprostatic disease (P ¼ 0.046). 12 The differences in mean levels were small with considerable overlap, however, and total testosterone was not a predictor of biochemical recurrence. 12 In other studies, low serum testosterone has been associated with advanced pathological stage, 13 higher tumor microvessel and androgen receptor density and higher Gleason scores, suggesting enhanced malignant potential, in men with newly diagnosed prostate cancer.
14 A high prevalence of occult prostate cancer has been reported in men with low serum testosterone levels. 15 Routine sextant prostate biopsies performed in 77 older men (mean age 58 years) with erectile dysfunction, low total or free serum testosterone levels randomly drawn throughout the day and normal digital rectal examination (DRE) and prostate-specific antigen (PSA) levels identified cancer in 11 (14%), of which 10 were aged over 60 years. Although other similar reports are lacking, such data are a reminder that men with LOH may harbor prostate cancer and close follow-up is essential when initiating testosterone therapy. Unmasking of clinically occult prostate cancer has been reported in a few cases of testosterone therapy, and this possibility should always be kept in mind. [16] [17] [18] Recently, Gaylis et al. 19 reported 20 patients retrospectively retrieved from six urology practices including some who may have inadequate monitoring for prostate cancer before and after receiving testosterone. In a retrospective series of 54 men with erectile dysfunction and low serum testosterone levels treated with testosterone replacement and followed for up to 82 months (mean 30.2 months), mean PSA increased from 1.86 to 2.82 ng/ml. 20 Six patients required prostate biopsy due to an increase in PSA above 4 ng/ml, but only one case (1.9%) of prostate cancer was identified. In a prospective study with 42-month follow-up of 163 hypogonadal men (mean age 51.5 years) treated with testosterone gel, mean serum PSA levels increased from 0.8570.06 ng/ml at baseline to 1.1170.08 ng/ml at month 6 and showed no further significant increases with continued testosterone treatment. 21 Only three (1.8%) men were identified with prostate cancer when the PSA became mildly elevated. 22 Such recommendations presumably stem from a time when most men with prostate cancer were diagnosed in advanced, usually incurable stages.
Administration of testosterone to men with active prostate cancer has been associated with adverse effects. 23 Among 52 patients with metastatic adenocarcinoma of the prostate treated with exogenous testosterone in anticipation of systemic chemotherapy, serious morbidity or mortality seemingly due to the testosterone administration occurred in eight cases (15%), and 87% experienced unfavorable subjective and/or objective responses. Moreover, the authors' review of the literature found reports on an additional 138 patients in whom an unfavorable subjective and/or objective response occurred in 93%. 23 In the current era, widespread PSA screening and transrectal ultrasound-guided prostate biopsies have resulted in the diagnosis of localized prostate cancer in an increasing number of men. Furthermore, modern radical prostatectomy produces PSA recurrence-free survival greater than 95% at 7 years in men with preoperative favorable staging of clinically localized adenocarcinoma of the prostate. 24 This review of 2091 men included 845 with T1c disease and 771 with T2a and 1050 with organ-defined disease. Two recent publications in the urological literature confirm that patients with minimally elevated PSA and Gleason scores of 7 or less at cancer detection are associated with high probability of finding organ-confined disease at the time of radical prostatectomy and PSA-free recurrence at 5-10 years following surgery. 25, 26 Undetectable PSA levels at follow-up can confirm the likelihood of cure. Modern radiotherapy for early stage disease also confers high recurrence-free survival, although PSA levels are usually not undetectable. The use of PSA after radiotherapy also has limitations and patients with optimal biochemical responses following radiotherapy may have late cancer recurrence. 27, 28 Modern radiotherapy for early stage disease also confers high recurrence-free survival, although PSA levels are usually not undetectable. 29, 30 With earlier detection and improved survival from early stage prostate cancer, it has been suggested that 'after a prudent period (this remains an uncharted territory) without recurrence of their cancer, the pros and cons of androgen replacement therapy should be carefully considered and the restriction may be lifted'. 31 
Case reports
In a retrospective review, the case records of seven hypogonadal men who had undergone curative radical prostatectomy for localized prostate cancer were identified. 7 All men had clinical symptoms of hypogonadism and low serum testosterone levels, including four whose levels were less than 100 ng/dl. Preoperative PSA was 4.4-6.6 ng/ml, surgical margins were negative in six (one man had a positive apical margin 11 years previously) and Gleason scores were 6 and 7 in all men. Four patients had received testosterone supplementation before the detection of prostate cancer. Each man was treated with an androgen preparation at varying time points after radical prostatectomy; five men received transdermal and two received intramuscular depot testosterone. After follow-up periods of up to 12 years, no biochemical or clinical evidence of cancer recurrence was found in any of the groups and all patients had concentrations of testosterone in the normal range. PSA levels were lower than 0.1 ng/ml in all patients following testosterone therapy. Clinical symptoms of hypogonadism improved uniformly and markedly.
In another study, testosterone therapy was given to 10 symptomatic hypogonadal men after radical prostatectomy, who had no evidence of disease by clinical and PSA criteria. Patients were given topical, transdermal or intramuscular formulations of testosterone. At a median follow-up of 19 months (range 9-29 months), no patient had detectable PSA and serum testosterone levels improved with therapy from a mean of 197767 to 5917180 ng/dl. 32 Men with high-grade prostate intraepithelial neoplasia (PIN), which is thought to be a prostatic precancerous lesion, are considered to be at increased risk for subsequent development of prostate cancer. In a study of 75 men with hypogonadism who underwent prostate biopsy before starting one year of testosterone replacement therapy, 20 men had PIN without frank cancer. 33 These PIN-positive patients were compared to 55 PIN-negative hypogonadal men. At baseline, PSA levels were similar in patients with and without PIN. After 1 year of testosterone replacement, PSA levels increased slightly in both PIN-negative and PIN-positive patients ( þ 0.25 and þ 0.33 ng/ml, respectively), with no significant difference between the two groups. Only 1 PIN-positive man was identified with prostate cancer. Rebiopsy for elevated PSA was performed in another four patients in the PINAndrogen therapy for hypogonadal men with prostate cancer J Kaufman negative group and two in the PIN-positive group, but none had cancer. The authors concluded that in this group of men at high risk of prostate cancer, testosterone supplementation is not contraindicated. 33 Although reports of testosterone treatment of hypogonadal men who have received attempted curative radiotherapy for their prostate cancer were not found, many studies show excellent apparent disease-free survival in patients with clinically localized prostate cancer who have received radiotherapy together with androgen suppression therapy. 29, 30 Some reports indicate that PSA less than 0.5 ng/ml at late follow-up is associated with apparent cure. 29, 30 However, due to the abovementioned limitations of PSA as a marker for disease recurrence following radiotherapy, administration of testosterone to a man who has received radiotherapy for prostate cancer should be considered very cautiously.
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Hypogonadism after androgen ablation therapy
Many men receive LH-RH agonists and antagonists in the neoadjuvant setting before radiotherapy or before radical prostatectomy. Recently, it has been suggested that radiation therapy given together with androgen suppression therapy may become the new standard for treatment of clinically localized prostate cancer. 34 Studies have shown, however, that even short-term LH-RH agonist therapy can produce severe and sustained hypogonadism so that patients may be cured of their prostate cancer but have severely symptomatic hypogonadism. 1 A single 3-month LH-RH agonist administered in the neoadjuvant setting to 13 men, aged 61-76 years, with clinically localized prostate cancer reduced testosterone levels to castrate levels. Testosterone levels were followed for 18 months. 1 Before therapy, median serum testosterone was 400 ng/dl (range 280-570) and no man fell below the lower limit of normal (241 ng/dl). After therapy, castrate testosterone levels (20 ng/dl) were maintained for 6 months and hypogonadal symptoms for 13.6 months. At 18 months, median testosterone was 230 ng/dl (range 140-360 ng/dl), with about 50% of these patients still significantly hypogonadal (o230 ng/dl). 1 Another prospective study of 68 men following withdrawal of androgen deprivation therapy evaluated the time taken for testosterone levels to return to normal. 35 Median time to normalization was 7 months. At 3, 6 and 12 months, 28, 48 and 74% of men had normal serum testosterone, respectively. 32 Serum testosterone took significantly longer to return to normal in patients receiving androgen deprivation therapy for 24 months or greater compared to those on therapy for less than 24 months (P ¼ 0.0034). In another study of 126 men who received treatment with gonadotropin-releasing hormone agonists for 6 months, the median time to normalization of testosterone levels after cessation of therapy was 16.6 weeks. 36 Thus, androgen deprivation has an effect on serum testosterone that extends beyond the cessation of treatment. It is likely that men who receive LH-RH agonists for prostate cancer and who remain severely hypogonadal will present for treatment for their hypogonadism. 34, 37 In one case, a 52-year-old man with raised PSA levels 35 months after radical prostatectomy was given adjuvant external beam radiation preceded by a 3-month injection of gosereline. The patient suffered sustained loss of libido, hot flushes and depression. He was then given supplemental testosterone 16 months after LH-RH agonist therapy, which produced significant relief of symptoms and no increase in PSA. A full year later, testosterone was still required to alleviate symptoms. 37 In another case, a 63-year-old man with prostate cancer and PSA 5.0 ng/ml underwent radical prostatectomy with findings of Gleason 7/10 and one seminal vesicle involved with cancer. He then received three successive 3-month gosereline injections and adjuvant radiotherapy. One year after surgery he complained of poor libido and hot flushes; PSA was undetectable but serum testosterone was in the castrate range at 28 ng/dl. At 3 months, when PSA remained undetectable and testosterone still measured only 45 ng/dl, he was started on 1% testosterone gel 5 g/day. Hypogonadal symptoms improved rapidly, and at follow-up, 26 months after surgery and 20 months after his last LH-RH agonist administration, he still remains hypogonadal (testosterone 194 ng/dl) and uses testosterone gel every 2 days (JK, personal communication).
It is certainly not indicated to routinely measure testosterone levels in all patients after treatment with LH-RH agonists, providing testosterone replacement if levels are low. However, in very select cases, that is, in men severely suffering from hypogonadal symptoms after transient testosterone suppression, treatment with testosterone replacement should be considered (Table 2) .
Conclusions
While the Third International Consensus Consultation on Prostate Cancer recommended that patients with prostate cancer should never receive testosterone supplementation therapy, recent data suggest that this recommendation can be modified in select cases, that is, when cancer is undetectable and the patient has documented hypogonadism. In men aged over 40 years without prostate cancer, DRE and PSA levels must be shown to be normal before testosterone replacement therapy is started. Followup monitoring at 3-6 months for the first year, then yearly thereafter has been recommended. 38 Patients already receiving testosterone therapy when their prostate cancer is detected and treated often are anxious to resume therapy, especially if their hypogonadal symptoms are severe. After radical prostatectomy, patients who are hypogonadal with favorable disease staging and undetectable PSA levels can be treated with testosterone therapy after careful counseling. 7 This discussion with patients should be documented and should address the pros and cons of testosterone replacement therapy following surgery for prostate cancer and include an evaluation of the risk/benefit ratio of such an approach. Patients should be treated cautiously, followed closely and testosterone levels should be brought into the low normal range. Testosterone therapy may also be considered to treat men who are hypogonadal following attempted curative treatment by irradiation and those persistently hypogonadal after short-term neoadjuvant LH-RH agonist therapy.
